http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
당뇨병에서 혈전탄성묘사기를 이용한 혈액응고 이상에 관한 연구
김승택(Seung Taik Kim),이복희(Bok Hee Lee),양성현(Sung Hyun Yang),이홍복(Hong Bock Lee),김은실(Eun Sil Kim),김병국(Byoung Kook Kim),이홍규(Hong Kyu Lee),고창순(Chang Soon Koh),민헌기(Hun Ki Min),이문호(Mun Ho Lee) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A The vasculopathy is the main complication leading to increased morbidity and mortality in long-standing diabetes, Since the platelets and coagulation system play an important role in the development of atherosclerosis, many studies have been done to elucidate the abnormalities of them without conclusive results. It is partly because of the lacking of definitive parameters demonstrating hypercoagulable state. We studied coagulation system as a whole in diabetes mellitus using thrombelastography which hes been considered simple and reliable method in the examination of coagulation process especially that of hypercoagulable state. In this study, We could conclude that bloods of diabetics with retinopathy were in hypercoagulable state and that the procoagulant substance(s) was present in the blood regardless of retinopathy, and that low dose of aspirin up to ~100 mg had no effect on the coagulation process of diabetics. Further study is warranted to the examination of the nature of procoagulant substances and the determination of optimal dosage of aspirin in diabetics.
급성 골수성 백혈병에서 Aclacinomycin , 6 - Thioguanine , ARA - C 복합 화학 요법의 치료 효과
이문호(Mun Ho Lee),이재훈(Jae Hoon Lee),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),최강원(Kang Won Choe),이홍복(Hong Bock Lee),김승택(Seung Taik Kim),서철원(Cheol Won Suh),김시영(Si Young Kim),방영주(Yung Jue Bang) 대한내과학회 1988 대한내과학회지 Vol.34 No.2
N/A Thirty-three patients with AML (untreated 22 and relapsing 11) were treated with induction chemotherapy with Aclacinomycin, 6-Thioguanine and Ara-C, followed by 2 courses of consolidation chemotherapy only, The results were as following: 1) Complete remission rate was 64% in previously untreated patients, and 55% in relapsing patients, respectively. 2) Median duration of response was 47+ weeks in previously untreated, and 26 weeks in relapsing patients, respectively. 3) 1n previously untreated patients, median survival was 58+ weeks. 4) In patients with relapsing AML, median survival of overall patients was 27 weeks. 5) Median period of granulocytopenia (<500/mm3) was 17 days and median time to complete remission was 27 days. Infection was suspected in most cases during hypoplastic phase and caustive organisms were gram negative bacteria, staphylococcus and fungi in most cases. 6) Among the potential prognostic variables including age, inital WBC count, performacne status and peripheral blast count, none was statistically significantly related to complete remission rate. 7) Toxicities including anorexia, nausea, vomiting, headache, alopecia and stomatitis were of mild degree and no demonstable acute cardiotoxicities were observed.
안구를 포함한 다발성 장기손상이 동반된 특발성 호산구증가 증후군 1예
박은재(Yeun Jae Park),조용범(Young Bum Joo),이지영(Ji Young Lee),신승용(Seung Yong Shin),이문희(Moon Hee Lee),이홍복(Hong Bock Lee),김철수(Chul Soo Kim) 대한내과학회 2000 대한내과학회지 Vol.58 No.6
N/A The idiopathic hypereosinophilic syndrome is a disorder marked by the sustained overproduction of eosinophils. The disease is characterized clinically by damage to multiple organs due to eosinophilic infiltration and mediator release rather than by the level of the absolute blood eosinophil count. We report a case of hypereosinophilic syndrome presenting multiple organ damages with eyeball involvement.(Korean J Med 58:692-697, 2000)
재생불량성 빈혈 환자의 생존 기간 및 예후 인자 : 224 예의 분석
서철원(Cheol Won Suh),양성현(Sung Hyun Yang),이홍복(Hong Bock Lee),허대석(Dae Seog Heo),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),이문호(Mun Ho Lee),유근영(Keun Young Yoo),안윤옥(Yoon Ok Ahn) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A Aplastic anemia is characterized by peripheral pancytopenia with bone marrow hypoplasia, There have been many suggestions that the clinical features of the patients with aplastic anemia in Korea would be somewhat different from that of western countries. But there is no reports regarding the survival rates and prognostic factors in the aplastic anemia patients of Korea. Thus clinical study was performed with 224 patients who were diagnosed as aplastic anemia at the department of internal medicine, Seoul National University Hospital (SNUH) during the past 10 years. The results are as the followings. 1) By Kaplan-Meier product limit estimation, median survival time of total patients was 72 months with estimated 5year survival rate of 54% and 10 year survival was 45.7%. 2) Severe aplastic anema patients showed median survival time of 8.3 months with 43.3% of 1 year survival rate and 32.7% of 5 year survival rate. 3) Non-severe cases had 1 year survival rate of 87.6% 5 year survival rate of 69.5% and 10 year survival rate was 58,1%. 4) In univariate data analysis by log rank test, severity, presence of infection, requirements of platelet transfusion, mean corpuscular volume of red cells, granulocyte count, platelet count, and corrected reticulocyte count had influence on the prognosis of the patients. 5) In multivariate data analysis by Cox regression hazard model, platelet and corrected reticulocyte count among the above prognostic factors had no statistically significant influence on the prognosis independently. These results from the retrospective study of our own patients showed some differences from the reported data of aplastic anemia patients in the western countries, and therefore confirmitive prospective studies concerning the survival and prognostic factors of Korean patients with this disease are needed.
마우스 태생간 조혈세포이식시 이식거부 반응을 극복하기 위한 조혈세포 용량 및 흉선세포의 역할에 관한 연구
김승택(Seung Taik Kim),박선양(Seon Yang Park),김병국(Byong Kook Kim),이홍복(Hong Bock Lee),김은실(Eun Shik Kim),계경채(Kyung Chae Kye),서정선(Jeong Sun Seo),강위생(Wee Saing Kang),이현순(Hyun Soon Lee),궁성수(Sung Soo Koong),이재훈(J 대한내과학회 1990 대한내과학회지 Vol.39 No.5
N/A To observe whether an increase in cell doses can overcome graft rejection, whether sustained chimerism is present, and whether fetal thymic cell transplantation has any effect on the survival and the cell dose needed, fetal liver transplantation was done from 17-18-day old DDY fetus to an ICR mouse (syngeneic transplantationl) previously irradiated. The results revealed that better survival was obtained, regardless of syngeneic of allogeneic fetal liver cell transplantion, through an increase of the cell dose. A 90F long- term survial was noticed with a cell dose of 15×108/kg in syngeneic transplantation. In the case of allogeneic transplantation, however, only a 50% long - term survival rate was observed with the same dose. The concurrent thymic cell transplantation had a good effect on the long - term survival and the reduction of cell dose required, The cell dose needed for the achievement of a 90% long - term survival in syngeneic and allogeneic transplantation was 5x108/kg and 15x108/kg, respectively The sustained chimerism was evident and the graft-versus-host disease was mininal in fetal liver cell transplantation. It was evident that fetal liver cell transplantation could be one of substitution in solving the problems of bone marrow transplantation The cell dose required to prevent graft failure decreased with fetal thymic cell transplantation The mechanism of the salutary effect of concurrent thymic cell transplantation is not yet to be elucidated.
Henoch - Shonein 자반증 환자의 혈중 제 13 혈액응고인자의 변동
신현춘(Hyun Choon Shin),박선양(Seon Yang Park),이진학(Jin Hak Lee),김병국(Byung Kook Kim),김노경(Neo Kyoung Kim),최지영(Jee Young Choi),박상철(Sang Chul Park),손영우(Young Woo Son),이홍복(Hong Bock Lee) 대한내과학회 1994 대한내과학회지 Vol.46 No.1
N/A Objectives: Factor X III is activated by thrombin to have transglutaminase activity that catalyzes the formation of ε-(Υ-glutamyl)lysine cross-links Between fibrin monomers rendering fibrin more elastie and less amenable to resolution by fibrinolytic agents, therefore diminished Factor X III activity leads to serious defect in hemostasis. Henoch-Sh5nlein purpura is different from other primary hemorrhagic diseases in that the disease connot be detected by routine tests in coagulation lab. But several reports have shown that hemorrhagic tendency of Henoch-Sh6nlein purpura is related to decreased level of the Factor X III. Method: Twenty one patients with Henoch-Sh5nlein purpura were collected from october 1988 and, Factor X III activity in the patients were compared to 10normal controls. The patients were diagnosed as Henoch- Shonlein purpura by typical clinical symptoms and giving mormal value in routine coagulation tests, The Factor XUI activity was assayed by isotope method. We also tried to find out the Factor X III activity variation according to clinical symptoms such as purpura and hematuria. Result: 1) The Factor XIII activity in normal controls and Henoch-Shonlein purpura were 3344±1126.7cpm and 2550.8±831.3cpm respectively. The degree of decreased Factor X III activity in patients compared to normal controls was statistically significant (p<0.05). 2) The Factor XIII activity during purpuric period was lower than that of non-purpuric period without statistical significance (p=0.1729). 3) Comparing hematuric period with non-hematuric period, the Factor X III activity during hematuric period was decreased without statistical significance (p=0, 2049). 4) There was more frequent hematuric symptom in purpuric period than non-purpuric period (p<0.05). Conclusion: We confirmed that the Factor XIII activity of patients with Henoch-Shonlein purpura was diminished, and the degree of reduction was correlated to the clinical symptoms such as prupura and hematuria. We consider that Factor X III activity monitoring would be helpful in diagnosis and determination of prognosis of Henoch-Shonlein purpura, furthermore replacement fo Factor X III concentrate could alter the course of the disease.
만성 골수성 백혈병 환자의 생존율 및 예후 인자 - 만성기 Ph1 환자의 분석 -
양성현(Sung Hyun Yang),서철원(Cheol Won Suh),방영주(Yung Ju Bang),박선양(Seon Yang Park),김병국(Byoung Kook Kim),김노경(Noe Kyeong Kim),이문호(Mun Ho Lee),김승택(Seung Taik Kim),이홍복(Hong Bock Lee) 대한내과학회 1988 대한내과학회지 Vol.35 No.4
N/A The prognostic significance of different clinical and laboratory findings at the time of diagnosis was anal- yzed among 136 patients with chronic myelogenous leukemia (CML). These patients were collected in the department of internal medicine of Seoul National University Hospital from January 1977 to December 1986. The incidence was not different between both sexes and peak incidence was third decade. The median survival time of all patients from diagnosis was 34.7 months. The cytogenetic study was performed in 110 patients of which 17% were Ph1-negative. These poor prognosis group, showing a shorter survival (14.4 months) than Ph1-positive ones (35.3 months), displayed lower platelet and white blood cell counts and lower percentage of myeloblast in peripheral blood. The prognostic analysis was restricted to the relatively good prognosis group, 85 Ph1-positive patients in chronic phase. From the univariate analysis, patient characteristics associated with shortened survival were age over 50 years old and peripheral basophils over 10%. These two factors were not interrelated. When patients were segregated according to the prognostic factors, it was possible to identify a low-risk group with median survival of 4S months, and a high-risk group with median survival of 1B months.
이홍복,이성규,변종훈,전인석,김웅봉,두창준,김정례 대한내분비학회 1988 Endocrinology and metabolism Vol.3 No.2
Adrenal myelolipoma is uncommon, nonfunctioning benign tumor, is composed of hemato-poietic cells and fat cells, which simulates the bone marrow. In most cases, this tumor is found incidnetally at autopsy. The advent of cross-sectional abdominal imaging technique has increased the incidence of this tumor, and the importance of the tumor has emphasized among the adrenal diseases. This tumor can be diagnosed by ultrasound and CT which show avasculr, highly fatty mass chatacterestically, and can be confirmed by fine-needle aspiration. Myelolipoma, in most, does not need any treatment, especially surgical removal. So, clinician do his or her best to avoid useless operation on facing such nonfunctioning adrenal tumor.